Vetter Contributes to Commercial Launches of Eight Customer Products in 2023
RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter, a leading globally operating Contract Development and Manufacturing Organization (CDMO), has joined the Science Based Targets Initiative (SBTi) membership group as of November 2023. The goal of the companies in the SBTi is to achieve climate neutrality by 2050, thus representing the strictest climate protection targets for companies worldwide. As a result, Vetter has committed to the 1.5 degrees of global warming target. To this end, the CDMO has presented a sustainability strategy with concrete steps to take through 2030, in which the effects of the planned dynamic growth related to CO2 emissions are already factored in. With the commissioning of the new photovoltaic plant and the conversion of another existing combined heat and power plant to biogas, both at its Ravensburg Center for Visual Inspection and Logistics, Vetter is already taking important steps towards Net Zero in 2023.
RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter, one of the world's leading Contract Development and Manufacturing Organizations (CDMO), is consistently pursuing improvements to its sustainability strategy. The globally-operating company released its second-annual sustainability report. For the first time, the pharmaceutical service provider headquartered in Ravensburg, Germany, also reports its Scope 3 emissions and shows its CO2 balance according to the requirements of the international Greenhouse Gas Protocol. Adding to its dynamic growth, the company was able to significantly reduce electricity consumption and CO2 emissions per euro of gross value added compared to the previous year. By 2029, the total emissions in relation to gross value added are to be reduced by ten percent compared to the base year 2019.
Steady growth, growing complexity: Key industry trends at BIO2023
Gold status for Vetter: Named Best Managed Company for the fourth time
Vetter, a global CDMO, is expanding capacities and services for the provision of clinical trial materials with the additional equipment for aseptic production and the expansion of storage capacities at the clinical site in Rankweil, Austria.
Vetter Performs Extraordinarily with Six Wins in the 12th Annual CDMO Leadership Awards
Vetter, a global Contract Development and Manufacturing Organization (CDMO) is helping partners to address challenges and for complex fill and finish solutions by offering comprehensive manufacturing services for clinical trials and supporting customer products path to commercialization. The company’s Skokie facility has helped to bring five new customer products to market since it began full operations in 2011, with another four expected to launch in the next few months.
RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter, a globally leading contract development and manufacturing organization (CDMO), has in place a comprehensive sustainability strategy that has made it a pioneer in this energy-intensive industry. The family-owned company is undertaking numerous initiatives aimed at making sustainability manifest in all facets for employees and acts as a motivator in encouraging them to participate. For the second time in a row, Vetter participated in a full week of life activities in the recent Sustainability Days of Baden-Wuerttemberg’s Sustainability Network. “To just speak about the topic of sustainability does not give it the credit it is due,” says Vetter Managing Director Thomas Otto. “That is why we are part of a proactive network of other companies. We need a strong community for sustainable development and we work hard to include all employees in the process.” Within this context, the CDMO has launched numerous sustainability activities that include various participatory events and lectures. This includes an information booth that traveled among company sites. Its aim is to sensitize all employees to the issue of sustainability and offer them easy-to-implement, hands-on suggestions that can enable greater sustainability in their professional and private lives.
ZUG, Switzerland, July 26, 2022 – MoonLake Immunotherapeutics AG (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has signed a Master Development Services Agreement with Vetter Pharma International GmbH (Vetter), a leading global contract development and manufacturing organization for fill and finish services, ranging from development support, including clinical manufacturing, through to commercial supply.